4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Diverticulitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 16 ongoing clinical trials involving Diverticulitis
Of the 16 trials,6 trials are in Phase II/III
Furthermore, 4 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Diverticulitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Diverticulitis, a Gastrointestinal condition. The largest number of ongoing clinical trials for Diverticulitisis conducted in North America. Europe is the other prominent region engaged in Diverticulitis-related drug trials.

Diverticulitis related clinical trial sponsor

Mayo Clinic, Jewish General Hospital, Uppsala University, Emmaus Life Sciences Inc, and Centre Hospitalier Universitaire de Dijon are a few notable clinical trials sponsors involved in Diverticulitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Diverticulitis

Ceftazidime (Fortaz, Fortam, Fortumset, Modacin, Glazidim, ceptaz), Cefepime and tazobactam (Duopime), and Atropine sulphate are among the key marketed drugs involving Diverticulitis.

Ceftazidime (Fortaz, Fortam, Fortumset, Modacin, Glazidim, ceptaz) is an anti-bacterial agent. It functions via Penicillin Binding Protein (PBP) Inhibitor mechanism of action. Ceftazidime is formulated as powder for solution for intramuscular or intravenous route of administration. It is used for the treatment of various bacterial infections caused by different bacterial species. Ceftazidime was first approved in 1983 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including GlaxoSmithKline LLC.

Cefepime and tazobactam (Duopime) is a fixed dose combination, acts as antibacterial agent. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. Cefepime and tazobactam are formulated as injectable powder for solution, for intravenous route of administration. Duopime is indicated for the treatment of uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections and complicated intra-abdominal infections. Cefepime and tazobactam is marketed solely in India by Orchid Pharma Ltd.